iwfal AMRN's Reduce It trial Interim 2 data is currently being collected and analyzed , so we may have more data ( or at least a DMC recommendation ( stop or no stop ) within the next 60 days .
I doubt it will be stopped at Interim 2
Vascepa is seen as working in multiple ways , improving the EPA/AA ratio , lowering inflammation , lowering triglycerides , strengthening fiborous caps on existing coronary plaques etc etc ....all in combination should lower CV events especially those diagnosed CAD with stents or verified coronary plaques.
My central argument is that high intensity Statins like Crestor are effective at lowering hsCRP ( Jupiter trial ) and since hsCRP has to be above 2 to even consider Novartis's really expensive drug ...payers will mandate optimal use of Statins and Vascepa ( if the Reduce it trial shows benefit ) first before agreeing to pay for Novartis's drug
JMO
I would be interested in your views on PRTO. Poster Poorgrad made the argument earlier that their first P 3 would fail . He was correct.
PRTO is now running a different, final P 3 re fistula patency with perhaps a lower hurdle to jump to be deemed a success. FDA has granted them break thru status.
Deerfield has put up $22m to enable PRTO to finish this final P 3 and Jonathan Leff ..partner from Deerfield is now on the BOD .
I'd be interested in your thoughts if U have time.
Loss of fistula patency is a major problem in dialysis ....wife ( a PA ) deals with it often .
Kiwi
Market Data 
Markets 
AI
